Gregory Colby
Experienced and energetic cell and molecular biologist, focused on discovery. Expertise in cell culture, cell-based assays, molecular biology and qPCR, ICC/high content imaging and target validation.
Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. For more information, contact info@mediartx.com
